These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36634897)

  • 1. Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension.
    El-Kersh K; Zhao C; Elliott G; Farber HW; Gomberg-Maitland M; Selej M; Garcia-Ferrer J; Benza R
    Chest; 2023 May; 163(5):1232-1244. PubMed ID: 36634897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension.
    Vicenzi M; Caravita S; Rota I; Casella R; Deboeck G; Beretta L; Lombi A; Vachiery JL
    PLoS One; 2022; 17(5):e0265059. PubMed ID: 35587927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk echocardiographic features predict mortality in pulmonary arterial hypertension.
    Austin C; Burger C; Kane G; Safford R; Blackshear J; Ung R; Ray J; Alsaad A; Alassas K; Shapiro B
    Am Heart J; 2017 Jul; 189():167-176. PubMed ID: 28625373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension.
    Haddad F; Spruijt OA; Denault AY; Mercier O; Brunner N; Furman D; Fadel E; Bogaard HJ; Schnittger I; Vrtovec B; Wu JC; de Jesus Perez V; Vonk-Noordegraaf A; Zamanian RT
    JACC Cardiovasc Imaging; 2015 Jun; 8(6):627-38. PubMed ID: 25981508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension.
    Austin C; Alassas K; Burger C; Safford R; Pagan R; Duello K; Kumar P; Zeiger T; Shapiro B
    Chest; 2015 Jan; 147(1):198-208. PubMed ID: 25211049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New risk model by right ventricle - pulmonary arterial coupling and inferior vena cava from echocardiography in patients with conventional low-intermediate risk pulmonary artery hypertension under targeted treatment.
    Yang L; Luo D; Huang T; Li X; Zhang C; Fei H
    Echocardiography; 2024 Jun; 41(6):e15850. PubMed ID: 38818775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
    Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP
    Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting high-risk pre-capillary pulmonary hypertension: an echocardiographic multiparameter scoring index.
    Zhai Y; Li A; Tao X; Gao Q; Xie W; Zhang Y; Chen A; Wang C; Lei J; Ding S; Cai Y; Zhai Z
    BMC Cardiovasc Disord; 2024 Jul; 24(1):384. PubMed ID: 39054410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
    Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
    Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension.
    Sahay S; Bhatt J; Beshay S; Guha A; Nguyen DT; Graviss EA; Nagueh SF
    Pulm Circ; 2022 Jan; 12(1):e12026. PubMed ID: 35506081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study.
    Shah T; Manthena P; Patel C; Chuah A; Hardin EA; Torres F; Bartolome SD; Chin KM
    Chest; 2022 Sep; 162(3):669-683. PubMed ID: 35460641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
    Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R
    Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.
    Anderson JJ; Lau EM; Lavender M; Benza R; Celermajer DS; Collins N; Corrigan C; Dwyer N; Feenstra J; Horrigan M; Keating D; Kermeen F; Kotlyar E; McWilliams T; Rhodes B; Steele P; Thakkar V; Williams T; Whitford H; Whyte K; Weintraub R; Wrobel JP; Keogh A; Strange G
    Chest; 2020 Jan; 157(1):162-172. PubMed ID: 31563497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right ventricular-pulmonary arterial coupling ratio derived from 3-dimensional echocardiography predicts outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension patients.
    Lan WF; Deng Y; Dai P; Wu DD; Hu J; Liao J; Meng H
    Lupus; 2024 Feb; 33(2):155-165. PubMed ID: 38182135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment.
    Fauvel C; Raitiere O; Boucly A; De Groote P; Renard S; Bertona J; Lamblin N; Artaud-Macari E; Viacroze C; Schleifer D; Dominique S; Pichon J; Jais X; Montani D; Sitbon O; Savale L; Humbert M; Bauer F
    J Heart Lung Transplant; 2022 Dec; 41(12):1761-1772. PubMed ID: 36202691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study.
    Benza RL; Boucly A; Farber HW; Frost AE; Ghofrani HA; Hoeper MM; Lambelet M; Rahner C; Bansilal S; Nikkho S; Meier C; Sitbon O
    J Heart Lung Transplant; 2022 Mar; 41(3):411-420. PubMed ID: 34848133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.